FDAnews
www.fdanews.com/articles/70571-metabasis-provides-further-information-on-cs-917-program

Metabasis Provides Further Information on CS-917 Program

April 1, 2005

Metabasis Therapeutics has announced that, while it is continuing to evaluate the implications of the serious adverse events as announced on March 16, the company has been informed that a Phase I clinical trial of CS-917 is continuing and that one or more additional Phase I clinical trials may be initiated soon to further evaluate the product candidate.

In parallel with this activity, Metabasis and Sankyo, together and separately, are evaluating what, if any, next steps should be taken in the CS-917 program.

Metabasis and Sankyo, its partner on the development of CS-917, recently halted two studies of the product following two serious adverse events occurred in an interaction study with the marketed diabetes drug metformin.